P/E ratio for Fate Therapeutics (FATE)
P/E ratio as of April 2024 (TTM): -1.78
According to Fate Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.78341. At the end of 2022 the company had a P/E ratio of -3.47.
P/E ratio history for Fate Therapeutics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.47 | -86.78% |
| 2021 | -26.2 | -39.98% |
| 2020 | -43.7 | 219.44% |
| 2019 | -13.7 | 28% |
| 2018 | -10.7 | 78.49% |
| 2017 | -5.99 | 152.97% |
| 2016 | -2.37 | -14.98% |
| 2015 | -2.79 | -30.23% |
| 2014 | -3.99 | -18.2% |
| 2013 | -4.88 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | 41.5 | -2,428.57% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -16.3 | 812.27% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -2.95 | 65.24% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 70.3 | -4,041.08% | 🇺🇸 USA |
 Avidity Biosciences RNA | -7.69 | 331.03% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.